ALNY News and Press, Alnylam Pharmaceuticals Inc. From 02/01/22

Design Therapeutics (NASDAQ:DSGN) announced the appointment of Jae Kim, M.D., as the company’s new Chief Medical Officer. Before joining Design (DSGN), Dr. Kim served as the chief medical officer at Avidity Biosciences, leading the advancement of its pipeline, including the start of a ...

Novartis (NYSE:NVS) is scheduled to announce Q4 earnings results on Wednesday, February 2nd, before market open. The consensus EPS Estimate is $1.44 (+7.5% Y/Y) and the consensus Revenue Estimate is $13.28B (+4.0% Y/Y). Over the last 2 years, NVS has beaten EPS estimates 75% of the time and h...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2021 on Thursday, February 10, 2022, before the U.S. financial markets open. Management ...

– Vutrisiran Met All 18 Month Secondary Endpoints, Including Statistically Significant Improvements in Neuropathy Impairment, Quality of Life (QoL), Gait Speed, Nutritional Status and Overall Disability, Relative to External Placebo – – Vutrisiran Continue...

– Company to Host Conference Call January 21 st at 8:30 am ET to Discuss Results – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present full 18-month results from the HELIOS-A...

– Achieved Full Year 2021 Preliminary Global Net Product Revenues of $662 Million, Representing 83% Annual Growth Compared to 2020 – – Maintained Strong Balance Sheet with Year-End Cash and Investments Balance of Approximately $2.4 Billion – ...

Do You Have These Biotech Stocks On Your Watchlist For January 2022? Biotech stocks have been one of the focal points of the stock market over the past two years. For obvious reasons, people and investors alike are always on the lookout for new developments against the coronavir...

If you're looking for stocks that can add a little excitement to your portfolio, biotech is a great place to start. Clinical-trial results and other binary events regularly send drugmaker stocks surging higher or lower overnight. If you're not sure where to start looking, you're not alo...

– Agreement will Bring Alnylam’s Proprietary siRNA Technology to Bear on Liver Target Identified by Novartis Researchers – – Alnylam and Novartis have Agreed to Collaborate on Discovery and Development of siRNA-based Targeted Therapy to Restore Func...

– Consistent Scientific Leadership Focused on Sustainable Innovation – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that Akshay Vaishnaw, M.D., Ph.D. has been appointed President. Dr. Vaishnaw joined A...